Company Filing History:
2 out of 60 
1 out of 488 
Years Active: 2022-2024
Title: Erica Evans Raab: Innovator in Cancer Treatment
Introduction
Erica Evans Raab is a prominent inventor based in Cambridge, MA (US). She has made significant contributions to the field of cancer treatment, holding a total of three patents. Her work focuses on developing selective RET inhibitors for treating cancers with RET alterations.
Latest Patents
One of her latest patents involves a RET inhibitor for use in treating cancer having a RET alteration. This patent discloses methods for treating subjects afflicted with cancer that has an activating RET alteration. The treatment involves administering an effective amount of a selective RET inhibitor, such as Compound 1 or its pharmaceutically acceptable salts. The recommended dosage ranges from 60 mg to 400 mg of the selective RET inhibitor once daily.
Career Highlights
Throughout her career, Erica has worked with notable companies in the pharmaceutical industry. She has been associated with Blueprint Medicines Corporation and Rigel Pharmaceuticals, Incorporated, where she has contributed to innovative cancer therapies.
Collaborations
Erica has collaborated with various professionals in her field, including her coworker Beni B Wolf. Their joint efforts have further advanced the research and development of cancer treatments.
Conclusion
Erica Evans Raab's work in developing RET inhibitors showcases her dedication to improving cancer treatment options. Her innovative patents and collaborations highlight her significant impact on the field of oncology.